|
1
|
Capitanio U and Montorsi F: Renal cancer.
Lancet. 387:894–906. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baldewijns MM, van Vlodrop IJ, Schouten
LJ, Soetekouw PM, de Bruïne AP and van Engeland M: Genetics and
epigenetics of renal cell cancer. Biochim Biophys Acta.
1785:133–155. 2008.PubMed/NCBI
|
|
5
|
Arsanious A, Bjarnason GA and Yousef GM:
From bench to bedside: Current and future applications of molecular
profiling in renal cell carcinoma. Mol cancer. 8:202009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cohen HT and McGovern FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lam JS, Shvarts O, Leppert JT, Pantuck AJ,
Figlin RA and Belldegrun AS: Postoperative surveillance protocol
for patients with localized and locally advanced renal cell
carcinoma based on a validated prognostic nomogram and risk group
stratification system. J Urol. 174:466–472; quiz 801. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tsui KH, Shvarts O, Smith RB, Figlin RA,
deKernion JB and Belldegrun A: Prognostic indicators for renal cell
carcinoma: A multivariate analysis of 643 patients using the
revised 1997 TNM staging criteria. J Urol. 163:1090–1095; quiz
1295. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thompson RH, Gillett MD, Cheville JC,
Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen
L, et al: Costimulatory B7-H1 in renal cell carcinoma patients:
Indicator of tumor aggressiveness and potential therapeutic target.
Proc Natl Acad Sci USA. 101:17174–17179. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Harshman LC, Choueiri TK, Drake C and
Stephen Hodi F Jr: Subverting the B7-H1/PD-1 pathway in advanced
melanoma and kidney cancer. Cancer J. 20:272–280. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thompson RH and Kwon ED: Significance of
B7-H1 overexpression in kidney cancer. Clinical Genitourin Cancer.
5:206–211. 2006. View Article : Google Scholar
|
|
12
|
Chandra Gupta S and Nandan Tripathi Y:
Potential of long non-coding RNAs in cancer patients: From
biomarkers to therapeutic targets. Int J Cancer. 140:1955–1967.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang L, Cai Y, Zhao X, Jia X, Zhang J, Liu
J, Zhen H, Wang T, Tang X, Liu Y, et al: Down-regulated long
non-coding RNA H19 inhibits carcinogenesis of renal cell carcinoma.
Neoplasma. 62:412–418. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hirata H, Hinoda Y, Shahryari V, Deng G,
Nakajima K, Tabatabai ZL, Ishii N and Dahiya R: Long noncoding RNA
MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and
interacts with miR-205. Cancer Res. 75:1322–1331. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang HM, Yang FQ, Yan Y, Che JP and Zheng
JH: High expression of long non-coding RNA SPRY4-IT1 predicts poor
prognosis of clear cell renal cell carcinoma. Int J Clin Exp
Pathol. 7:5801–5809. 2014.PubMed/NCBI
|
|
16
|
Song S, Wu Z, Wang C, Liu B, Ye X, Chen J,
Yang Q, Ye H, Xu B and Wang L: RCCRT1 is correlated with prognosis
and promotes cell migration and invasion in renal cell carcinoma.
Urology. 84:730.e1–e7. 2014. View Article : Google Scholar
|
|
17
|
Li CY, Liang GY, Yao WZ, Sui J, Shen X,
Zhang YQ, Peng H, Hong WW, Ye YC, Zhang ZY, et al: Identification
and functional characterization of microRNAs reveal a potential
role in gastric cancer progression. Clin Transl Oncol. 19:162–172.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chan AC, Fan ST, Poon RT, Cheung TT, Chok
KS, Chan SC and Lo CM: Evaluation of the seventh edition of the
American Joint Committee on Cancer tumour-node-metastasis (TNM)
staging system for patients undergoing curative resection of
hepatocellular carcinoma: Implications for the development of a
refined staging system. HPB. 15:439–448. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sui J, Li YH, Zhang YQ, Li CY, Shen X, Yao
WZ, Peng H, Hong WW, Yin LH, Pu YP, et al: Integrated analysis of
long non-coding RNAassociated ceRNA network reveals potential
lncRNA biomarkers in human lung adenocarcinoma. Int J Oncol.
49:2023–2036. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Miao Y, Sui J, Xu SY, Liang GY, Pu YP and
Yin LH: Comprehensive analysis of a novel four-lncRNA signature as
a prognostic biomarker for human gastric cancer. Oncotarget.
8:75007–75024. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zeng JH, Liang L, He RQ, Tang RX, Cai XY,
Chen JQ, Luo DZ and Chen G: Comprehensive investigation of a novel
differentially expressed lncRNA expression profile signature to
assess the survival of patients with colorectal adenocarcinoma.
Oncotarget. 8:16811–16828. 2017.PubMed/NCBI
|
|
22
|
Zhao Q and Sun J: Cox survival analysis of
microarray gene expression data using correlation principal
component regression. Stat Appl Genet Mol Biol. 6:Article 16. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou X, Huang Z, Xu L, Zhu M, Zhang L,
Zhang H, Wang X, Li H, Zhu W, Shu Y, et al: A panel of 13-miRNA
signature as a potential biomarker for predicting survival in
pancreatic cancer. Oncotarget. 7:69616–69624. 2016.PubMed/NCBI
|
|
24
|
Heagerty PJ, Lumley T and Pepe MS:
Time-dependent ROC curves for censored survival data and a
diagnostic marker. Biometrics. 56:337–344. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu Z, Shao W and Shen Y, Ji M, Chen W, Ye
Y and Shen Y: Characterization of new microsatellite markers based
on the transcriptome sequencing of Clematis finetiana. Hereditas.
155:232018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sho S, Court CM, Winograd P, Russell MM
and Tomlinson JS: A prognostic mutation panel for predicting cancer
recurrence in stages II and III colorectal cancer. J Surg Oncol.
116:996–1004. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Krishnan B, Rose TL, Kardos J, Milowsky MI
and Kim WY: Intrinsic genomic differences between African American
and white patients with clear cell renal cell carcinoma. JAMA
Oncol. Mar 24–2016.(Epub ahead of print). doi:
10.1001/jamaoncol.2016.0005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Eichelberg C, Junker K, Ljungberg B and
Moch H: Diagnostic and prognostic molecular markers for renal cell
carcinoma: A critical appraisal of the current state of research
and clinical applicability. Eur Urol. 55:851–863. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu Y, Liu H, Liu W, Zhang W, An H and Xu
J: β1,6-N-acetylglucosaminyltransferase V predicts recurrence and
survival of patients with clear-cell renal cell carcinoma after
surgical resection. World J Urol. 33:1791–1799. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin YL, Wang YL, Fu XL and Ma JG: Aberrant
methylation of PCDH8 is a potential prognostic biomarker for
patients with clear cell renal cell carcinoma. Med Sci Monit.
20:2380–2385. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Y, Wang DL, Yan HY, Liao JY, He JH,
Hu KS, Deng WX, Wang YJ, Xing HT, Koeffler HP, et al: Genome-wide
study of ER-regulated lncRNAs shows AP000439.3 may function as a
key regulator of cell cycle in breast cancer. Oncol Rep.
38:3227–3237. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li CY, Liang GY, Yao WZ, Sui J, Shen X,
Zhang YQ, Peng H, Hong WW, Ye YC, Zhang ZY, et al: Integrated
analysis of long non-coding RNA competing interactions reveals the
potential role in progression of human gastric cancer. Int J Oncol.
48:1965–1976. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zheng S, Zheng D, Dong C, Jiang J, Xie J,
Sun Y and Chen H: Development of a novel prognostic signature of
long non-coding RNAs in lung adenocarcinoma. J Cancer Res Clin
Oncol. 143:1649–1657. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yao J, Chen Y, Wang Y, Liu S, Yuan X, Pan
F and Geng P: Decreased expression of a novel lncRNA CADM1-AS1 is
associated with poor prognosis in patients with clear cell renal
cell carcinomas. Int J Clin Exp Pathol. 7:2758–2767.
2014.PubMed/NCBI
|
|
36
|
Xue S, Li QW, Che JP, Guo Y, Yang FQ and
Zheng JH: Decreased expression of long non-coding RNA NBAT-1 is
associated with poor prognosis in patients with clear cell renal
cell carcinoma. Int J Clin Exp Pathol. 8:3765–3774. 2015.PubMed/NCBI
|
|
37
|
Flippot R, Mouawad R, Spano JP, Rouprêt M,
Compérat E, Bitker MO, Parra J, Vaessen C, Allanic F, Manach Q, et
al: : Expression of long non-coding RNA MFI2-AS1 is a strong
predictor of recurrence in sporadic localized clear-cell renal cell
carcinoma. Sci Rep. 7:85402017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jin P, Wang J and Liu Y: Downregulation of
a novel long non-coding RNA, LOC389332, is associated with poor
prognosis and tumor progression in clear cell renal cell carcinoma.
Exp Ther Med. 13:1137–1142. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shi D, Qu Q, Chang Q, Wang Y, Gui Y and
Dong D: A five-long non-coding RNA signature to improve prognosis
prediction of clear cell renal cell carcinoma. Oncotarget.
8:58699–58708. 2017.PubMed/NCBI
|
